Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Up 6.8% – Should You Buy?

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX)’s stock price was up 6.8% during mid-day trading on Tuesday . The company traded as high as $1.47 and last traded at $1.40. Approximately 16,975 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 1,003,951 shares. The stock had previously closed at $1.31.

Theriva Biologics Stock Up 6.8 %

The company has a market cap of $3.89 million, a PE ratio of -0.04 and a beta of 1.22. The stock’s 50 day simple moving average is $1.30 and its two-hundred day simple moving average is $1.75.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.